MRT 6160
Alternative Names: MRT-6160Latest Information Update: 22 Aug 2024
At a glance
- Originator Monte Rosa Therapeutics
- Class Antineoplastics; Antirheumatics; Small molecules
- Mechanism of Action Proto oncogene protein c vav degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders